JP Morgan Initiates Coverage On Seaport Therapeutics with Overweight Rating, Announces Price Target of $42
Seaport Therapeutics
Seaport Therapeutics SPTX | 0.00 |
JP Morgan analyst Tessa Romero initiates coverage on Seaport Therapeutics (NASDAQ:
SPTX) with a Overweight rating and announces Price Target of $42.
